Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Journal for Immunotherapy of Cancer|March 3, 2026
Priorities for local immunotherapy research and drug developmentJames M Isaacs, Jason LukeJournal of Oncology Practice|March 2, 2012
Improving quality and addressing the rising costs of cancer care: two birds, one stoneJason Luke, Joshua Mirkin, Peter BachAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Approaches to High-Risk Resected Stage II and III MelanomaMelinda Yushak, Janice Mehnert, Jason Luke, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 14, 2023
The role of autophagy in hypoxia-induced radioresistanceRhianna Mae Hill, Matthew Fok, Gabrielle Grundy, et al.Clinical & Experimental Metastasis|May 4, 2018
Review of diagnostic, prognostic, and predictive biomarkers in melanomaJacob S Ankeny, Brian Labadie, Jason Luke, et al.Biorxiv : the Preprint Server for Biology|May 19, 2023
Orthogonal CRISPR screens to identify transcriptional and epigenetic regulators of human CD8 T cell functionSean R McCutcheon, Adam M Swartz, Michael C Brown, et al.Journal for Immunotherapy of Cancer|February 4, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysisCameron Wood, Liliana Lyniv, James M Isaacs, et al.Nature Genetics|November 9, 2023
Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screensSean R McCutcheon, Adam M Swartz, Michael C Brown, et al.Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.Pageof 2